Thomson Reuters Announces Nominations for Top Pharma Deals of the Year 2014 Breakthrough Awards to honor the best deal in the categories of 'Biopharmaceutical Licensing' and 'Mergers and Acquisitions'
PHILADELPHIA, April 1, 2014 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, unveiled the nominations for the Allicense 2014 Breakthrough Awards for Deal of the Year, honoring the top global deal in each of two categories: 'Biopharmaceutical Licensing' and 'Mergers and Acquisitions' (M&A), as identified by Thomson Reuters Recap, the premier analysis tool for biopharmaceutical business deal making. The awards — to be determined by public vote — will be presented Tuesday, April 29, at Allicense, a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development.
The award nominees, five contenders in each of the two categories: Licensing and M&A, were determined by Thomson Reuters deals analysts after a thorough analysis of Recap information and other criteria that examined hundreds of deals negotiated throughout 2013. Members of the pharmaceutical community are invited to choose the top breakthrough deals in each category by submitting a ballot by end of day Friday, April 25.
"We are pleased to announce the nominees for the Allicense 2014 Breakthrough Awards for Deals of the Year and to celebrate the best in deal-making and partnering efforts that consistently drive the industry forward," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences. "It is appropriate that members of the pharmaceutical community are the final factor in determining the 2013 deals that most exemplify creative innovation."
The list of nominees includes:
- Pfizer and Lilly: tanezumb
- OncoMed Pharmaceutical and Celgene: demcizumab and five biologics
- Monderna Therapeutics and AstraZeneca: mRNA therapeutics for cardiometabolic, renal, and cancer targets
- Ablynx and AbbVie: ALX-0061
- ISIS Pharmaceuticals and Biogen Idec: Therapies for neurological diseases using Isis' antisense technology
- Aragon Pharmaceuticals and Johnson & Johnson: ARN-509, ARN-810; ARN-912
- Amplimmune, Inc and Medimmune (AstraZeneca): AMP-224, AMP-110, AMP-514
- Okairos AG (seller) / GlaxoSmithKline (buyer): ProCvax, TerCvax
- Lotus Tissue Repair (seller) / Shire (buyer): Recombinant collagen Type VII (rC7)
- Trius Therapeutics (seller) / Cubist Pharmaceuticals (buyer): TR-701, GyrB/ParE
Visit the Allicense website to view in-depth details on each of the nominated deals, as well as to cast your vote for the Deal of the Year. Online voting ends on Friday, April 25, with live voting taking place at the Allicense conference until 5 p.m. PDT on Tuesday, April 29.
Allicense 2014 is the world's premier event for deal making, licensing and business development. Industry professionals discuss key issues facing the sector and learn about innovative deals and structures of the future. Allicense 2014 takes place Tuesday, April 29, and Wednesday, April 30, in San Francisco, California. Learn more about the event and register here.
Learn more about Thomson Reuters Recap.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.
SOURCE Thomson Reuters